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Twenty-five years ago, the development of
molecular biology and recombinant DNA technol-
ogy promised breakthroughs in infectious
disease research. Since then, these methods have
slowly teased out molecular secrets of microbial
infection, gene by gene. Now, with the advent of
whole-genome sequencing, a new revolution in
infectious disease research has begun. Genomics
is a top-down approach to the study of genes and
their functions, taking advantage of DNA
sequences of complete genomes. Determining the
DNA sequence of a complete genome is a major
activity of genomics. Although basic DNA-
sequencing methods have remained the same,
advances in automation and informatics enable
determination of whole microbial genome
sequences  in <2 years. Complete knowledge of an
organism’s genetic makeup allows exhaustive
identification of candidates for virulence genes,
vaccine and antimicrobial targets, and diagnos-
tics. The genomes of at least 13 pathogenic
bacteria have been sequenced (Table 1),
representing >20,000 putative genes. The
genomes of at least 28 other pathogenic bacteria
are being sequenced, promising >40,000 addi-
tional genes. This tally does not include an
equally large number of nonpathogenic bacteria
undergoing whole-genome sequence analysis.
These new data dwarf previous methods of gene
discovery, allowing many new genetic ap-
proaches to understanding pathogenesis.
Raw Material
Genome projects produce different types of
data, depending on the stage and goals of the
project (Table 2). The goal of most projects is a
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Table 1. Whole-genome sequencing of bacterial pathogensa
Bacterium Status (ref.)
Actinobacillus In progress
  actinomycetemcomitans
Bacillus anthracis In progress
Bartonella henselae In progress
Bordetella bronchiseptica In progress
B. parapertussis In progress
B. pertussis In progress
Borrelia burgdorferi Finished (1)
Campylobacter jejuni Finished
Chlamydia pneumoniae Finished (2)
C. trachomatis Finished (3)
Clostridium difficile In progress
Enterococcus faecalis In progress
Escherichia coli K12 Finished (4)
E. coli O157:H7 In progress
Haemophilus influenzae Finished (5)
Helicobacter pylori Finished (6,7)
Listeria monocytogenes In progress
Mycobacterium avium In progress
M. leprae In progress
M. tuberculosis Finished (8)
Mycoplasma genitalium Finished (9)
M. mycoides In progress
M. pneumoniae Finished (10)
Neisseria gonorrhoeae In progress
N. meningitidis In progress
Porphyromonas gingivalis In progress
Pseudomonas aeruginosa In progress
P. putida In progress
Rickettsia prowazekii Finished (11)
Salmonella serotype Typhi In progress
S. Typhimurium In progress
Shigella flexneri In progress
Staphylococcus aureus In progress
Streptococcus mutans In progress
S. pneumoniae In progress
S. pyogenes In progress
Treponema denticola In progress
T. pallidum Finished (12)
Ureaplasma urealyticum Finished
Vibrio cholerae In progress
Yersinia pestis In progress
aMuch of these data were taken from the TIGR website (see
Table 2). In-progress genome projects are those that are
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Table 2. Availability of sequence data
Internet site Organization Description
www.ncbi.nlm.nih.gov/Entrez/Genome/ National Institute of Biotechnology Many genomes represented
  org.html   Information
http://www.tigr.org/tdb/index.shtml The Institute for Genomic Research Genomes sequenced by
  TIGR
www.stdgen.lanl.gov Los Alamos National Laboratory Sexually transmitted
  disease pathogens
http://www.micro-gen.ouhsc.edu/ University of Oklahoma Genomes sequenced at the
  Univ. Oklahoma
www.pasteur.fr/recherche/banques/Colibri/ Institut Pasteur Colibri, database of the
  Escherichia coli genome
pedant.mips.biochem.mpg.de/ Pedant Many genomes represented
http://www.ncgr.org/research/sequence/ National Center for Genome Many genomes represented
  Resources
http://www.kazusa.or.jp/cyano/ Kazusa DNA Research Institute Cyanobase, cyanobacterial
  genome information
www.sanger.ac.uk/Projects/Microbes/ Sanger Centre Genomes sequenced by
  the Sanger Centre
www.genetics.wisc.edu/ University of Wisconsin Genomes sequenced by the
  Univ. Wisconsin Genome
  Center
www.zmbh.uni-heidelberg.de/ University of Heidelberg Mycoplasma pneumoniae
  M_pneumoniae/genome/Results.html   genome
utmmg.med.uth.tmc.edu/ Univ. Texas Houston Medical Treponema pallidum
  treponema/tpall.html   School
http://chlamydia-www.berkeley.edu:4231/ Univ. Cal. – Berkeley Chlamydia genomes
evolution.bmc.uu.se/~siv/gnomics/ Uppsala University Rickettsia prowazekii
http://www.genomecorp.com/ Genome Therapeutics Corp. Genomes sequenced at GTC
   sequence_center/index.html
genome.wustl.edu/gsc/Projects/ Washington University Genomes sequenced at
  bacteria.shtml   Washington Univ.
http://www.genoscope.cns.fr/externe/ Genoscope Genomes sequenced at
  English/Projets/Resultats/rapport.html   Genoscope
www.genome.washington.edu Univ. of Washington Pseudomonas aeruginosa
www.pseudomonas.com Pathogenesis Corp. P. aeruginosa
pbil.univ-lyon1.fr/emglib/emglib.html Enhanced Microbial Genomes Many genomes represented
  Library
www.pasteur.fr/recherche/banques/ Institut Pasteur TubercuList, database of
  TubercuList/   the Mycobacterium
   tuberculosis genome
finished contiguous DNA sequence of the
bacterium’s chromosome(s). The error frequency
in a finished sequence has never been precisely
measured but is thought to be one error
(frameshift or base substitution) in 103 to 105
bases. Other types of errors, such as rearrange-
ments, are probably even more rare. Even at the
higher end of this error frequency, approximately
one error per gene, the sequence is still very
useful for database searches and most applications.
Finished genome sequences are annotated to
varying degrees. The two most important
annotations are the predicted protein coding
sequences, generally called open reading frames
(ORFs), and what they resemble in database
searches (see below). Strictly speaking, an ORF is
any stretch of codons that does not include a
chain termination codon; however, only a subset
of all the ORFs present in the genomic sequence
actually encodes proteins and is used in genome498 Emerging Infectious Diseases Vol. 6, No. 5, September–October 2000
Genomics
annotation. These ORFs are identified by
predicting coding sequences. The predictions are
90% to 95% accurate. In addition, many
untranslated RNAs (mainly tRNA and rRNA
genes) are identified and annotated. Various
other features may be part of the annotation,
including elements of the predicted protein
structure, such as secondary structure motifs
and membrane spanning regions. Unfortunately,
annotation rarely extends to noncoding regions,
where promoters and regulatory signals reside.
Similarly, structural features of DNA (e.g., Z-
DNA) are rarely analyzed, which may bear on
regulation or genome structure. At this time,
the emphasis is overwhelmingly on gene
products since these convert sequence data into
useful products.
A near-universal trend among public (but not
private) genome projects is the early release of
unfinished sequence data, sometimes referred to
as (rough) draft sequences. This release can occur
when as little as 1x coverage (coverage being the
number of bases read in DNA sequencing
reactions, divided by the genome size) of the
genome has been obtained by random sequenc-
ing; for an average-size 2-MB genome, this may
mean 4,000 sequencing reads. Most genomes will
have been sequenced at least once, although the
sequence will have a high error rate and many
gaps, and some regions of the genome will not be
represented. These random sequence reads are
assembled by a computer program that looks for
overlaps between the individual sequences and
generates consensus sequences, i.e, a sequence in
agreement with most of the individual reads
(present in stretches of contiguous nucleotides or
contigs). Since there are many gaps in the
sequence, hundreds to thousands of contigs are
produced by this process, with a wide range of
sizes (typically from 100s to 10,000s of  bases)—
although always much smaller than the total
genome. Collections of contigs can be searched for
matches to sequences of interest, allowing
identification of relevant contigs and specific
DNA sequences within them. This analysis prior
to release of the completed sequence speeds the
application of results from genome projects.
Finding Hints in Sequences
Several approaches can be used to analyze
whole-genome sequences for candidate virulence
factors and for vaccine and antimicrobial targets.
Comparing predicted coding sequences to
sequences in databases (e.g., GenBank), using
the BLAST program (13,14) identifies matches to
known genes. Typically, approximately 20% of
the predicted ORFs in a genome do not match
anything in GenBank, while another 10%–20%
match genes of unknown function, often
discovered in other genome projects. The fraction
of genes of unknown function in a genome has
been remarkably constant in microbial genome
sequences, regardless of the number of genomes
sequenced and available for comparison. Thus,
the comparison approach is useful in recognizing
good candidates among genes whose functions
have been described; it is not particularly useful
in discovering new virulence functions or motifs.
For microbes related to well-studied patho-
gens, such as gram-positive cocci or gram-
negative enteric pathogens, comparing sequence
data yields many database matches or “hits.” For
organisms more distantly related to well-studied
groups, results are more modest. When this
approach was used for the spirochete Treponema
pallidum, only 70 genes out of 1,041 could be
recognized as potential virulence factors (15).
Since a number of these had previously been
described as antigens or membrane proteins
without a function implicating them in infection,
only half of the 70 genes could be matched to a
function associated with virulence or host
interaction in another pathogen. Of these, the
evidence for some of the existing database
annotations was slim, at times only theoretical
and not based on solid experiments. These
spurious annotations can be readily perpetuated
because of the volume of new genes entered
without critical evaluation. Thus for T. pallidum,
for which approximately 40% of the total ORFs
did not match a gene with any annotated function
(12), virulence factors are likely to be novel, and
other methods for their discovery are needed.
Databases that do not search for matches to
whole genes or proteins can also be searched.
These include databases of protein motifs such as
BLOCKS (a database of conserved regions of
protein families, obtained from multiply aligned
sequences [16,17]) and ProDom (18,19). Hits to
these databases are based on much smaller
conserved regions and do not require extensive
similarity elsewhere in the sequence, as may be
the case with whole-gene matches. More general
characteristics of protein sequences, such as
those of membrane proteins, can also be used to
identify genes of interest. The rationale is thatVol. 6, No. 5, September–October 2000 Emerging Infectious Diseases 499
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proteins involved in host interactions (likely to be
virulence factors) should be localized to the cell
surface or be secreted. Transmembrane se-
quences can be predicted by a variety of programs
such as PHD (20,21); signal sequences can be
identified with programs such as SIGNALP
(22,23). Transmembrane and signal sequences
and other characteristics are included in
annotations in databases (e.g., the one for
sexually transmitted disease pathogens) (Table 2).
Other sequence-based clues have been used
in this type of analysis. Tandem repeats of
simple (e.g., mono-, di-, tri-, or tetranucleotide)
sequences are often found in or near certain
virulence genes, called contingency genes
(24,25). Because changes in the number of copies
of repeats alter expression or other properties of
these genes, leading to antigenic or other types of
variation, this feature can be analyzed to identify
genes. Finally, analysis of untranslated regula-
tory regions, though not extensive, appears to be
a fruitful area for future studies. A genetic
method for identifying new virulence factors is to
find genes that are coregulated with known
virulence factors (26). This type of analysis could
be used in silico (analysis by computer). Motifs
commonly associated with binding sites for
regulators, such as inverted repeats, could be
identified in regulatory regions of genes involved
in pathogenesis or matching known virulence
factors. These motifs could then be used to search
for other regulatory regions containing the motif.
The associated genes would then be candidates
for virulence factors.
In summary, a number of strategies have
been developed to mine genomic sequences for
virulence factor genes. Other approaches will
likely be developed. The availability of this
information on easily accessible electronic
databases will make this a  routine tool in future
studies of pathogenic microbes. All of these
factors constitute a powerful set of new tools for
research planning and experimental design and
interpretation.
Genetics Meets Genomics
One criticism of the sequence-gazing ap-
proach is that it is not hypothesis based.
However, the theoretical analysis of genomic
sequence described above requires laboratory
validation of conclusions, which are the
hypotheses that drive experimental design. The
availability of sequence data not only generates
hypotheses but also greatly speeds the task of
testing them.
In systems with good genetics and suitable
models to test virulence, the sequence allows
design and construction of clones for making
targeted knockout mutants—a type of mutation
where a gene’s function is knocked out by
inserting DNA into or deleting the gene. These
mutational methods are usually  based on a
polymerase chain reaction assay (PCR), since the
sequence allows primers to be designed to
amplify and clone the key sequences. In some
organisms, wholesale construction of such
mutants is under way (27). One can determine if
inactivation of a gene leads to attenuation of
infection in a model system. If genetic analysis is
not feasible, it is still possible to test whether
immunization with a gene product (either the
whole protein or part of it) can lead to protection
in a model. While this testing does not provide as
strong a case for a role in virulence as a null
mutant (a mutation that causes complete loss of
function in a gene), it indicates whether the
protein is a good vaccine target. In this case, the
sequence allows design and construction of
clones overexpressing the protein of interest in a
more manipulable host (again by PCR amplifica-
tion of key sequences). Often, identification and
purification of proteins in the natural host are
formidable tasks. However, whole-genome se-
quencing allows overproducers to be constructed
in Escherichia coli or other workhorse strains.
Both of the methods described above can
determine if a gene is functional when virulence
is affected. However, when there is no effect,
there is no indication of whether the gene is real
or functional. Determining if the gene is
transcribed and translated is then desirable.
Reverse transcription (RT)-PCR, again basing
primer design on the genome sequence, is often
performed for such analysis and can be extended
to determine operon structure in the genome.
Genomewide transcription analysis is performed
with DNA arrays. Protein prepared in a
surrogate host can be used to detect antibodies in
serum from infected persons, which is particu-
larly relevant for surface protein candidates for
immunodiagnostics. An immunopositive reaction
indicates that a gene is transcribed and translated.
Scanning for Function
The sequence-to-mutant method described
above is appropriate when genes of interest can500 Emerging Infectious Diseases Vol. 6, No. 5, September–October 2000
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Figure 1. Genetic footprinting. Shown are two
neighboring genes from the whole genome. Gene A
encodes a virulence factor; gene B does not. Neither
gene is essential. After transposon mutagenesis,
multiple insertions (vertical triangles) are obtained in
each gene (only two are shown). Polymerase chain
reaction (PCR) primers (horizontal arrows) to the start
of the gene and the transposon are used to amplify the
sequences between insertion and start of gene. After
electrophoresis, a characteristic set of bands is seen for
each gene, corresponding to the location of insertions.
Mutants of genes A and B grew under permissive
conditions (Ap, Bp). Only mutants of gene B (Bn) grew
under nonpermissive (animal model) conditions.
be identified by sequence analysis. However,
there are likely to be novel genes that do not
match known functions or domains and do not
have characteristics used to identify surface
proteins. How would one identify a secreted
protein with a function not previously described
and the sequence characteristics of a soluble
protein? Or what about essential genes, targets
for antimicrobial drugs, that may encode
cytoplasmic proteins, some of which are novel
and do not match known proteins? The methods
described above would not be sufficient to
identify these important functions.
Several methods that bridge this gap have
been proposed for whole-genome function
analysis. In all cases, the genome is scanned by
exhaustive transposon mutagenesis, and mutants
are screened en masse for functional properties.
These methods can identify essential genes,
virulence factors, and other types of phenotypes.
Genetic footprinting (28,29), which was
developed for yeast, is also applicable to bacteria
(Figure 1). This method depends on the complete
genome sequence since PCR primers are made to
the ends of each gene in the genome. A saturating
set of transposon insertions is isolated at random
in the genome, so all genes receive multiple
insertions. The mutants are pooled, and the
culture is split and grown under permissive and
nonpermissive conditions. For essential genes,
there is no permissive condition. For virulence
functions, a permissive condition might be broth
culture, and a nonpermissive condition might be
an animal model. After growth, DNA is extracted
from the cultures, and each mutant gene is
assayed by PCR using one primer for the end of
the gene and one primer for the end of the
transposon. Each gene is assayed separately and
generates a series of bands, each corresponding
to a different insertion in the gene. Comparison of
the permissive and nonpermissive conditions
allows the identification of mutants that drop out
(that is, do not grow) under nonpermissive
conditions. An essential gene mutant gives no
products in either permissive or nonpermissive
samples. Mutants in a gene required for infection
would give products with the permissive but not
the nonpermissive culture. Other genes would
give products under both conditions. In this way,
one assays function by “knocking out” all genes.
Signature-tagged mutagenesis (30) is an-
other dropout mutant approach, but its scheme
for tracking each gene differs (Figure 2). The
transposon used for random mutagenesis has
been prepared to have an index region in which
each transposon has a different sequence. This
region can be amplified by PCR. The resulting
product can be used as a hybridization probe to
uniquely identify the transposon that encodes it.
The initial set of random insertion mutants is
arrayed on a master and then pooled and grownVol. 6, No. 5, September–October 2000 Emerging Infectious Diseases 501
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Figure 2. Signature-tagged mutagenesis. The box on the right shows a transposon insertion, indicating the index
region and location of polymerase chain reaction (PCR) primers that amplify the segment unique to each
transposon.
under permissive and nonpermissive conditions,
as above. The mutants that emerge in each
growth regimen are then collected, and their
index regions are amplified and used to hybridize
to the master array of original mutants. This
process allows the identification of mutants that
dropped out during the selection. Regions
flanking the insertions in mutants of interest are
then sequenced and compared to the genomic
sequence to find inactivated gene(s). An
important difference between signature-tagged
mutogenesis and genetic footprinting is that in
genetic footprinting each gene is specifically and
systematically assayed, relying on the genome
sequence. Thus, essential genes are readily found
since they have no mutations. On the other hand,
signature-tagged mutagenesis assays mutants
randomly and thus could not determine that a
gene could not be mutated until a large number of
mutants had been tested. Nevertheless, this
method has been widely used to detect virulence
factor genes (31-36).
Additional methods using transposon scan-
ning to find genes with essential or other
functions will likely be developed. The methods
described above often require more genetic
manipulations than can be performed in some
pathogenic organisms. Recent advances to
overcome these limitations include using in vitro
transposition to generate mutants (37) as well as
new transposons with broad host ranges (38).
One Genome Is Not Enough:
Comparative Genomics
Comparative genomics, which requires input
of multiple genomic sequences, is relatively new,
and the microbial genome era is just entering truly
large-scale production. The first whole-genome502 Emerging Infectious Diseases Vol. 6, No. 5, September–October 2000
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comparisons were of strains phylogenetically
separated, since these were the only genomes
available. Much can be learned about evolution
from comparing such disparate organisms, but
certain lessons can best be gleaned from
comparing more closely related genomes.
Recently, such comparisons have been per-
formed with the genomes of Mycoplasma
genitalium and M. pneumoniae (39,40), two
strains of Helicobacter pylori (6), Chlamydia
trachomatis and C. pneumoniae (2), and draft
sequences of Salmonella enterica serotype
Typhimurium (41) and S. Typhi (42) with the
completed sequence of E. coli. These studies
promise to provide pertinent, but different
information about virulence functions than the
analyses presented above. One type of compari-
son is between strains of the same genus that
infect different tissues.  This comparison results
in lists of genes that are common or different; this
outcome may ultimately be correlated with
tissue-specific virulence factors. Moreover, genes
that are common but not found in other genera
may reflect unique morphologic characteristics
as well as host interactions. A second type of
comparison is between two strains of the same
species. Here, one is identifying regions of
variability that are to be avoided in choosing
targets for vaccine or antimicrobial therapy and
that may be less important in infection. This is
one of the newer and very promising areas in
microbial genomics. Web sites that provide
genomic data will also likely provide methods of
comparative analyses, similar to methods
provided by the Bugspray feature on the sexually
transmitted diseases database site.
Solutions without Answers
If the ultimate aim of pathogen genome
sequencing is the development of vaccines,
therapeutics, and diagnostics, candidate genes
may be identified before the mechanism of
infection is understood. The genome sequence is
the “parts list,” used to test each gene product for
its potential usefulness by various high-
throughput methods. DNA vaccines constitute
one of the few documented approaches for this
purpose (43-45). In this case, genes targeted for
vaccine use are cloned in expression vectors, and
their efficacy for vaccine use is tested without
ever studying the gene product. The potential of
this approach was shown with Mycoplasma. A
more commonly tried method in industry, often
presented at conferences although not published,
is to express a subset of the total set of genes in
E. coli, purify the products, and test them in a
mouse or other small animal model. The subset of
genes is usually selected by computational
criteria, i.e., their similarity to known virulence
genes or indications that the protein is surface
localized or secreted. In addition, expression
analysis, using array technology, for instance, is
often used to identify genes expressed in the host.
Furthermore, many organism-specific genes
without database matches are included in the
subset, which may comprise 500 to 1,000 genes.
Expression in E. coli is accomplished by using
standard vectors, but usually as a fusion protein
to a component that can simplify purification
(histidine-tag, glutathione-S-transferase, or
thioredoxin, for example). Many genes may fall
by the wayside because of difficulties in
expression or purification, but even if only 10%
make it through, at least 50 to 100 candidates are
available for testing in animal models. Such a
large number of candidates easily surpasses the
number of proteins identified for testing by
traditional means. Clearly, discovering genes to
test no longer limits the identification of useful
gene products; rather, the new bottleneck is
finding suitable models for high-throughput
testing of efficacy. In any event, it is likely that
candidate genes will be identified and enter
industrial development long before researchers
understand their role in infection.
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